Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med's Autism Clinical Study

Rhea-AI Summary

Adia Nutrition (OTCQB: ADIA) announced that independent IRB BeyondBound approved its patent-pending clinical study protocol for an Autism Spectrum Disorder (ASD) trial run by Adia Med of Winter Park LLC.

The randomized study will enroll 100 children ages 3–12 to compare combined glutathione plus umbilical cord blood-derived stem cells versus glutathione alone. Key outcomes include social interaction, communication, behavior, and quality of life.

Patient recruitment is expected to begin in January 2026. Study details have been submitted to ClinicalTrials.gov and are in final review before public posting.

Positive

• IRB approval received from BeyondBound for ASD protocol
• Planned enrollment of 100 children ages 3–12
• Patient recruitment targeted to start in January 2026
• Study submitted to ClinicalTrials.gov and in final review

Negative

• No clinical results or efficacy data available yet
• ClinicalTrials.gov listing not yet publicly visible

Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).

IRB Approval Email

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/278050_adia_irb_approved_screenshot.jpg

The approved study, titled "Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study", will enroll 100 children ages 3-12 and investigate whether combining glutathione with umbilical cord blood-derived stem cells provides greater therapeutic benefits compared to glutathione alone. Key outcome measures include potential improvements in social interaction, communication, behavior, overall quality of life, and other core areas impacted by ASD.

Study details have been submitted to ClinicalTrials.gov and are currently in the final review stage before becoming publicly visible. Adia Nutrition will notify shareholders and interested parties once the listing is live.

Patient recruitment is expected to begin in January 2026, with regular updates provided on enrollment and study progress.

"This approval from BeyondBound is a key milestone in advancing potential new options for individuals and families affected by autism," said Larry Powalisz, CEO of Adia Nutrition Inc. "We are truly grateful to our Medical Director, Dr. Evan Thomas MD PhD, for leading this important study with exceptional diligence and expertise. We also extend our sincere thanks to the team at BeyondBound for their thorough review, unwavering diligence, and confidence in our protocol. We're optimistic about the insights this study could bring and look forward to moving it forward responsibly."

This autism study will serve as the foundational model for Adia Med's planned additional clinical studies in 2026 targeting various other conditions. Looking ahead, Adia Med intends to conduct numerous further studies and act as sponsor for research conducted at partner clinics across a range of desired indications.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278050

FAQ

What did Adia Nutrition (ADIA) announce on December 15, 2025 about its autism study?

Adia announced IRB approval from BeyondBound for a patent-pending ASD clinical protocol and plans to enroll 100 children ages 3–12.

When will Adia Nutrition (ADIA) begin recruiting patients for the autism trial?

Patient recruitment is expected to begin in January 2026.

What intervention will Adia Med study in the ADIA autism trial and what is it compared against?

The study will test combined glutathione plus umbilical cord blood-derived stem cells versus glutathione alone.

How many participants will the Adia Nutrition (ADIA) autism study enroll and what ages?

The approved protocol plans to enroll 100 children between ages 3 and 12.

Is the Adia Nutrition (ADIA) trial listed on ClinicalTrials.gov yet?

Study details have been submitted and are in final review before the ClinicalTrials.gov listing becomes publicly visible.

What outcomes will Adia Nutrition (ADIA) measure in the autism study?

Key outcome measures include social interaction, communication, behavior, overall quality of life, and other core ASD areas.